Status epilepticus is an emergency; however, prompt treatment of patients with status epilepticus is challenging. Clinical trials, such as the ESETT (Established Status Epilepticus Treatment Trial), compare effectiveness of antiepileptic medications, and rigorous examination of effectiveness of care delivery is similarly warranted. We reviewed the medical literature on observed deviations from guidelines, clinical significance, and initiatives to improve timely treatment. We found pervasive, substantial gaps between recommended and "real-world" practice with regard to timing, dosing, and sequence of antiepileptic therapy. Applying quality improvement methodology at the institutional level can increase adherence to guidelines and may improve patient outcomes.
W hile "time is brain" has traditionally described the pathophysiology of stroke, our present-day understanding of status epilepticus reaffirms this mantra. Status epilepticus, prolonged seizures or multiple seizures with incomplete return to baseline, is an emergency that requires prompt treatment. [1] [2] [3] On the cellular level, changes in receptor trafficking and neuropeptide expression occur within minutes to encourage a hyperexcitable state. 1, 4 Clinically, seizure cessation becomes less likely as time to therapy lengthens. 5 Yet despite its importance, timely treatment is not achieved for the majority of patients presenting with status epilepticus. Status epilepticus has an incidence of 10 to 40 per 100,000 population, and the impact is considerable. 4 Mortality is estimated at 20% to 30%, 2, 4 and up to 23% of patients will deteriorate in neurological function. 6 Additionally, its estimated annual direct inpatient costs in the United Status are >$4 billion. 4 While age and etiology are critical determinants of prognosis, 7 prolonged seizure duration is associated with higher mortality and morbidity, 8, 9 worse functional outcome, 10 and increased risk of subsequent epilepsy. 11 Furthermore, seizure duration is the only modifiable prognostic factor 7 and can be improved by expeditiously administering antiepileptic medication.
Expert opinion supports utilizing a protocol to facilitate urgent treatment. 12, 13 The initial first-line agent should be administered within 5 to 10 minutes of seizure onset, a second-line agent within 20 to 40 minutes, and a third-line agent within 60 minutes. 14, 15 Class I evidence supports using a benzodiazepine as the first-line agent, but weaker evidence guides choice of a second-line agent and beyond. 13, 15, 16 The 2016 Guideline Committee of the American Epilepsy Society proposed fosphenytoin, valproic acid, and levetiracetam as second-line options, 15 
and the ESETT (Established Status Epilepticus
Treatment Trial) is currently underway to compare effectiveness of these three second-line therapies. 17, 18 Given that prompt therapy is a critical component of effective therapy, delivery of care warrants similarly rigorous examination.
We performed a review of the literature to characterize observed divergences from recommended guidelines, consider their clinical significance, and explore initiatives to improve adherence to treatment protocols. We aim to identify opportunities and approaches to
Materials and Methods

Search Strategy and Selection Criteria
The electronic database PubMed was searched in June 2017 using the following criteria to identify delays and deviations from status epilepticus treatment protocols: "("status epilepticus" [ . This search strategy yielded 1,064 studies; publications preceding 2000 were filtered out yielding 766 studies. The abstracts of these 766 studies were screened and papers were excluded if they met any of the following criteria: (1) unrelated to prolonged seizures or status epilepticus; (2) no measure of deviation from protocol/recommendations in drug timing, dosing, and/or sequence of therapies; or (3) an interventional study. Only the initial publication was included in the case of republished data with secondary analysis. This approach yielded 17 studies. A subsequent search used the additional search terms of quality, improve*, intervention*, pathway, and protocol 19 ; this strategy identified three additional studies that used interventions to expedite treatment of patients presenting with clinical status epilepticus.
Definitions
For the purpose of comparing between studies, "first-line therapy" is defined as a benzodiazepine (typically lorazepam, diazepam, or intramuscular midazolam), "second-line therapy" is defined as the initial nonbenzodiazepine drug (typically phenytoin, fosphenytoin, valproic acid, levetiracetam, or phenobarbital), and "third-line therapy" is defined an anesthetic medication (typically propofol or intravenous [IV] midazolam). Status epilepticus and/or prolonged seizure are defined differently within each study, and the working definition used for inclusion in each study is reported within Tables 1 and 2 .
Statistical Analysis
Study sample size and statistical analysis varied greatly across papers. For this review, we have reported median, mean, percentage, range, interquartile range (IQR), confidence interval (CI), and/or p value as provided by each study's authors. Our tables provide complete reporting of the statistics as made available in each original paper.
Results
Of the 17 studies identified, all assessed delivery of firstline therapy for patients presenting in status epilepticus, five studies assessed delivery of second-line therapy and five studies assessed delivery of third-line therapy. Seven studies included only pediatric patients and seven studies included only adult patients. Nine studies considered exclusively patients presenting with convulsive status epilepticus. All studies but four reviewed patient records retrospectively; two prospective studies gathered information at the time of the patient encounter and two studies analyzed prospectively collected data sets. Authors considered time-related aspects of care such as time from seizure onset to administration of first-line, second-line, and third-line agents (Table 1) and medication-related aspects of care such as drug sequence and dosing (Table  2) . Last, authors examined adherence to the treatment protocol, either institution-specific or consensus guidelines, and analyzed the time to seizure cessation and patient outcome (Table 3 ). Three quality improvement (QI) reports were identified in our review; all three studies focused on interventions for pediatric patients presenting with clinical status epilepticus. Guidelines for the reporting of QI work have been published previously, 20 and these QI reports are summarized with attention to these guidelines in Table 4 .
Prehospital Care
From time of seizure onset, the median delays to paramedic arrival ranged from 12.5 (IQR, 18; range, 0-95) to 30 minutes 21, 22 and to hospital presentation ranged from 30 minutes (range, 5-120) to 1 hour 45 minutes. [21] [22] [23] [24] [25] Before reaching the emergency department (ED), antiepileptic medication was administered to 34% (16 of 47) to 51% (56 of 109) of patients. [21] [22] [23] [24] 26, 27 One study found that no patients received treatment during ambulance transfer. 24 When out-of-hospital first-line therapy was administered, the median delay was 1 hour 10 minutes.
21
Time to Therapy A >30-minute delay to first-line treatment was observed for 17% (26 of 157) to 64% (97 of 151) of patients, [29] [30] [31] [32] with the median delays to first-line therapy ranging from 30 to 70 minutes 21, 22, 27, 33, 34 (see Table 1 ).
Median delays to second-line treatment ranged from 69 minutes to 3 hours. Median delays to third-line treatment ranged from 2 hours 38 minutes to 3 hours. 27, 33, 34 In these studies, the ranges for delay were very wide, from minutes to several days. A study of international practice observed that 16% of patients received third-line therapy within 1 hour. 35 Treatment of nonconvulsive status epilepticus and epilepsia partialis continua started significantly later, with 18% (17 of 92) of patients receiving initial treatment at >24 hours compared to 0% (0 of 70) of patients with Treatment delivery can be expedited through use of an automated, standardized order set.
A standardized protocol can reduce progression to status epilepticus and can improve antiepileptic toxicity.
ANNALS of Neurology
A systematic analysis of the components of delay concluded that delay to first-line drug was best explained by delay in calling paramedics and the clumsiness of administering rectal medication; delay to second-line therapy was largely because paramedics did not have the ability to administer IV fosphenytoin; and delay to thirdline therapy might be attributable to diagnostic delay 33 .
Choice and Dosing of Agents
While nearly all pediatric patients received a benzodiazepine as the first-line agent, 23, 24, 27 patients admitted to the intensive care unit (ICU) and patients treated for febrile status epilepticus had higher rates of nonbenzodiazepine initial therapy, 11% and 7% respectively 22, 25 (see Table 2 ). Benzodiazepines were not used as the initial treatment in 7% or less of adult patient samples, 26, 33, 37 except for a world-wide survey of status epilepticus treatment that reported 67% of patients did not receive a benzodiazepine as a first-line therapy. 35 When benzodiazepines were administered, 22% (32 of 146) to 90% (159 of 176) of patients received suboptimal weightbased dosing. 22, 25, 26, 28 Because of improper drug choice, dosage, or sequence, 29% (13 of 45) to 61% (77 of 126) of patients were not treated according to protocol. 24, 28, 33, 36, 37 A common violation of the protocol was more than two administrations of benzodiazepines (rather than the recommended escalation to a second-line drug), which was observed in 23% (41 of 179) to 49% (23 of 47) of pediatric patients 22, 24, 27, 28 and may be associated with greater risk of respiratory depression. In one study, 43% (10 of 23) of pediatric patients treated with >2 doses of benzodiazepines had respiratory compromise compared to 13% (3 of 24) patients treated with 2 or fewer doses. 24 Another study demonstrated a relative risk of intubation of 2.3 (95% CI, 1.4-3.9; p 5 0.002) for pediatric patients treated with >2 benzodiazepine doses.
28
Associations Between Time to Therapy and Seizure Cessation A positive relationship between seizure duration and delayed first-line, second-line, and/or third-line therapy was demonstrated for both pediatric and adult patients presenting with convulsive status epilepticus. 22, 27, 31, 34, 37 A correlation between seizure duration and treatment delay was also noted in a cohort of adult patients not limited to convulsive seizures. 34 When considering functional outcome in adults presenting with status epilepticus, patients treated in the ED within 1 hour of seizure onset had better recovery than when treatment was initiated beyond 1 hour (82% vs 46%; p < 0.05). 21 In-hospital mortality and poor functional outcome were associated with treatment delay of >30 minutes; however, this association was weakened when adjusted for seizure etiology, seizure duration, and nonconvulsive status epilepticus 32 (see Table 3 ).
Conversely, several authors observed no association between protocol adherence and patient outcomes. Length of ICU stay was not associated with delay to first-line or second-line therapy in children presenting with convulsive status epilepticus. 27 One study of adults presenting with convulsive status epilepticus found that while adherence to recommended treatment was associated with shorter seizure duration, the outcomes of morbidity, mortality, duration of hospital stay, and intubation were not associated with adherence to recommended drug sequence. 37 Another study reported that treatment latency did not relate to the outcomes of mortality and new disability; though there was no significant association between treatment adherence and outcome, medication sequence appeared to have a greater influence than medication dose. 36 International survey of treatment practice found paradoxically that patients who received third-line therapy later had better outcomes. 35 Initiatives to Improve Protocol Adherence The first phase of each QI initiative consisted of multidisciplinary engagement and careful surveillance of current practice at individual institutions. Observed causes of variation and delays included failure to correctly identify time of seizure onset, inconsistent physician orders, delayed decision making regarding when to administer drugs, lack of standing orders for medication as needed, varying experience of staff and personnel, knowledge gaps, inefficient communication, and issues with availability of antiepileptic medication. [38] [39] [40] All three studies chose to standardize treatment by creating or modifying a treatment protocol. Following employment of a linear, single-agent protocol for pediatric patients presenting with impending status epilepticus, 93% (51 of 55) of seizures were appropriately treated with first-line midazolam and 86% (6 of 7) were appropriately treated with phenytoin as second-line therapy (no comparison group available). 38 In another study that used an automatically activated electronic order set for any pediatric patient with a diagnosis of seizure, the mean time from impending status recognition to firstline therapy improved (3.74 vs 7.72 minutes; p < 0.0001) as did delay to second-line therapy (25 vs 49.5 minutes; p < 0.0001). 39 Implementing a standardized treatment protocol for neonatal status epilepticus reached 80% protocol adherence with regard to drug sequence and order. Additionally, there was a reduction in mean maximum serum phenobarbital concentration (41.0 vs 56.8ug/ml) as intended and a 10% reduction in seizures progressing to status epilepticus. 40 
Discussion
Recent major advances in our understanding of the pathophysiology of status epilepticus have not yet translated to more rapid treatment in clinical practice. The above studies demonstrate pervasive delays in treatment of status epilepticus; 17% to 64% of patients have a >30-minute delay to first-line therapy.
With only 31% to 54% of patients receiving treatment before arrival at the hospital, the prehospital period represents a substantial missed opportunity for timely intervention (Table 5) . While it is difficult to decrease the time until an emergency call is made or until paramedics reach a patient, superior options for rescue medication administered by family and caregivers are certainly within reach. Furthermore, the journey to the hospital has been shown to typically be >30 minutes, and while outfitting paramedics with the capability to deliver second-line therapy or early polytherapy has not yet been shown to improve outcomes, 41 it warrants further study. 42 Given class I evidence for use of benzodiazepines as first-line therapy, it is alarming that some studies have shown that 7% to 67% of patients are not initially receiving benzodiazepines. Furthermore, there is variability in dosing of benzodiazepines, often with patients 43 ).
Simplifying and clarifying recommended first-line agent dosing would be helpful. Discontinuity and discordance between prehospital and in-hospital treatment protocols may be leading to confusion regarding choice and dosing of first-line therapy. An explicit single, continuous protocol bridging prehospital to in-hospital treatment would be advantageous. While all patients presenting in status epilepticus can experience treatment delay, it is both intuitive and supported by substantial evidence that nonconvulsive status epilepticus is treated later than convulsive status epilepticus because of diagnostic delay. Parallel opportunities exist for educating emergency personnel and family members regarding the clinical presentation of nonconvulsive status epilepticus as well as for developing technology to advance electrographical diagnosis in the field and immediately upon arrival to the ED. Such technologies might include simplified electroencephalogram (EEG) systems deployable around the clock by non-EEG-trained staff; these systems could either accurately identify status epilepticus at the bedside or transmit data to the cloud for rapid remote interpretation by certified professionals.
There is strong evidence of a positive relationship between treatment delay and seizure duration; however, whether or not adherent treatment improves morbidity and mortality is thus far equivocal. This uncertainty is likely attributed to confounding factors; for example, the paradoxical finding that patients who received late thirdline therapy had better clinical outcomes 35 may be explained by slower escalation of therapy for less-severe clinical presentations. 35, 36 Variable patient presentations, methods, and measurements across studies lead to divergent conclusions in the existing literature. In particular, some studies do not consider seizure type (convulsive vs nonconvulsive), which is likely to confound associations between treatment and outcome. Other studies adjust outcomes for the duration of status epilepticus, which may obscure the full impact of initiating treatment early. The threshold for dichotomizing timely versus delayed treatment (>30 vs >60 minutes) is potentially impactful because of evolving changes in neurotransmission. Furthermore, it may be that one element of adherence (drug sequence) is more important than another (drug dose). For future studies, it would be hugely beneficial to develop standardized quality indicators of treatment adherence and to use consistent clinical outcomes, covariate considerations, and definitions of status epilepticus.
Nearly all of these observational studies (15 of 17) were performed retrospectively or by review of previously collected data. As such, seizure onset and cessation times become difficult to accurately extract and clinical decision making is nearly impossible to evaluate. Potential causes of treatment delay may be conjectured, but the subtleties and details of individual patient presentations are lost when data are reviewed retrospectively. Collecting high-quality data in real time would elucidate causes of treatment delays; however, prospective data abstraction is extremely laborious. Hopefully, methods of seamless, real-time data collection will advance as public reporting of performance grows. Innovation, such as the automated extraction of clinical information with innovative technologies to create a visualization of treatment, 44 more nimble tracking, and more robust data infrastructure, would be invaluable to the field. While the paucity of data regarding cause of delays in status epilepticus treatment is frustrating, the discipline of QI is particularly well suited to this inquiry. QI differs from traditional research in that the primary focus is understanding and improving a local process. As such, the initial phase consists of a deep dive into the "why" of a problem by examining the local environment, observing the current practice, and performing root cause analysis. Variation in choice and timing of drug therapy in status epilepticus appears to be a problem across institutions; a powerful response would be the development of common protocols that could be disseminated nationally and then tailored to local needs.
Conclusion
There is a significant gap between the recommended treatment of status epilepticus and current practice. Neurologists have long been invested in the study of antiepileptic drug effectiveness; however, attention must also be paid to successful delivery of care. More effective treatment of patients with status epilepticus may be achieved when care delivery is optimized through rigorously examining current practice, collaborating across disciplines, and creating pragmatic treatment protocols. Coupling established QI methods to technological innovation in data collection promises to make this approach even more powerful. These methods should be utilized by neurologists and other health care professionals who treat status epilepticus. 061779, 2016). Additional support for this work was provided by the Mirowski Family Fund and the Family of Jonathan Rothberg.
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